Submitted by pharmamanufacturing on Wed, 02/23/2011 - 11:07
Big consulting groups like to publish big reports on big topics, to establish their authority and expertise, and of course to impress potential clients with how smart and visionary they are. The glossy PDFs have big titles, and are punctuated by bold statements about industry transformations.
Category: Pharmaceutical industry management Pharmaceutical researchers Process Analytical Technologies The Pharma Industry Pfizer Pharma Workforce and Staffing Pharmaceutical Mergers and Acquisitions Pharmaceutical Industry CEOs Quality Accountability Pharmaceutical Industry Reputation Pfizer Sandwich Pfizer Wyeth Pharma Ceo's Wy-pfi Merger
Submitted by pharmamanufacturing on Thu, 02/03/2011 - 09:38
Submitted by pharmamanufacturing on Fri, 09/18/2009 - 11:36
Are we spending our drug development dollars wisely? It's not a new debate, but a new study from U.S. medical researchers suggests no. Industry funding of drug R&D is aligned with the needs of high-income countries, the report says (no big surprise), and that funding is not producing the...
Category: Pharmaceutical researchers Pharmaceutical Industry Conflicts of Interest Clinical trials Phrma
Submitted by pharmamanufacturing on Mon, 12/15/2008 - 21:16
A new report conducted by doctors at the University of California-San Francisco claims that pharmaceutical companies are still not being transparent in the reporting of their clinical trials, finding that some are up to five times more likely to report positive findings than negative.
Submitted by pharmamanufacturing on Thu, 11/20/2008 - 11:36
Four universities--Hawaii, MIT, Purdue, and Rutgers--are collaborating on an effort, with support from the National Science Foundation, to apply modern analytical methods to traditional medicines in order to learn more about their properties. The researchers will use informatics and bioinformatics to establish a more cohesive database on traditional medicines.
Submitted by pharmamanufacturing on Mon, 11/17/2008 - 09:43
Our contributing editor and resident expert on PAT, Emil Ciurczak, sent a nice follow up to my recent article on Virginia Tech Professor Harold McNair. Ciurczak writes:
Category: Pharmaceutical industry management human resources Pharmaceutical sales and marketing Pharmaceutical researchers FDA Human condition
Submitted by Ciurczak, Emil on Fri, 02/22/2008 - 14:32
As my wife and I were returning by train from "The City" last night (if you need to ask "which city?" you don't live on the east coast), we were listening to a group of teenagers. It was satisfying to actually hear them discussing the presidential election.
Category: Uncategorized Blogroll management human resources Pharmaceutical sales and marketing Pharmaceutical researchers Human condition
Submitted by Ciurczak, Emil on Wed, 02/20/2008 - 10:03
Just saw a remarkable segment on the Today show; there is a trend to use women in India as surrogate mothers. One main reason? It's cheaper! Now, where have we heard that one before? Granted, the women in the "womb-for-hire" program have more health care than the average Indian...
Category: Blogroll Pharmaceutical industry management management human resources Pharmaceutical sales and marketing Pharmaceutical researchers Process Analytical Technologies
Submitted by Ciurczak, Emil on Mon, 12/31/2007 - 12:05
I know all you Pharma executives have been busy this time of year, so, to help you catch up, I'd like to suggest a few resolutions for the Pharma industry (starting this year): 1. STOP trying to equate bigger with better. Every merger costs thousands of jobs.
Category: Pharmaceutical industry management Pharmaceutical sales and marketing Pharmaceutical researchers FDA Chemistry
Submitted by Ciurczak, Emil on Sat, 12/08/2007 - 22:06
I had just submitted my piece on stability testing for Therapeutic Dose when a thought hit me: why do we routinely tolerate unknowns in our stability samples? According to ICH Q3B(R2), if a patient's daily dose of a drug is greater tha one gram, 0.05% "unknown" material is allowed.